Last updated on April 2017

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)


Brief description of study

To determine the maximum tolerated and / or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY1436032 and to characterize its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy in patients with mIDH1-R132X advanced acute myeloid leukemia (AML)

Clinical Study Identifier: NCT03127735

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

University of Southern California Keck School of Medicine
Los Angeles, CA United States
  Connect »

Bayer Clinical Trials Contact

University of Florida-Gainesville
Gainesville, FL United States
  Connect »

Bayer Clinical Trials Contact

Northside Hospital - Atlanta
Atlanta, GA United States
  Connect »

Bayer Clinical Trials Contact

Northwestern Memorial Hospital
Chicago, IL United States
  Connect »

Bayer Clinical Trials Contact

University of Chicago
Chicago, IL United States
  Connect »

Bayer Clinical Trials Contact

Roswell Park Cancer Institute
Buffalo, NY United States
  Connect »

Bayer Clinical Trials Contact

Mount Sinai Medical Center
New York, NY United States
  Connect »

Bayer Clinical Trials Contact

Montefiore Medical Center
The Bronx, NY United States
  Connect »

Bayer Clinical Trials Contact

Wake Forest Baptist Health
Winston-Salem, NC United States
  Connect »

Bayer Clinical Trials Contact

Ohio State University
Columbus, OH United States
  Connect »

Bayer Clinical Trials Contact

University of Pennsylvania
Philadelphia, PA United States
  Connect »

Bayer Clinical Trials Contact

Thomas Jefferson University
Philadelphia, PA United States
  Connect »

Bayer Clinical Trials Contact

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Heidelberg
Heidelberg, Germany
  Connect »

Bayer Clinical Trials Contact

Klinikum rechts der Isar
München, Germany
  Connect »

Bayer Clinical Trials Contact

Medizinische Hochschule Hannover (MHH)
Hannover, Germany
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Essen
Essen, Germany
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Leipzig A R
Leipzig, Germany
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Charite zu Berlin
Berlin, Germany
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Hamburg Eppendorf (UKE)
Hamburg, Germany
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.